Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Treating bacterial virulence systems: we are not there yet.

Huang YJ, Bittner EA, Frank D, Wiener-Kronish J.

Intensive Care Med. 2012 Jul;38(7):1087-8. doi: 10.1007/s00134-012-2561-9. Epub 2012 Apr 20. No abstract available.

2.

Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial.

van Delden C, Köhler T, Brunner-Ferber F, François B, Carlet J, Pechère JC.

Intensive Care Med. 2012 Jul;38(7):1118-25. doi: 10.1007/s00134-012-2559-3. Epub 2012 Apr 20.

PMID:
22527075
3.

Lack of impact of selective digestive decontamination on Pseudomonas aeruginosa ventilator-associated pneumonia: benchmarking the evidence base.

Hurley JC.

J Antimicrob Chemother. 2011 Jun;66(6):1365-73. doi: 10.1093/jac/dkr112. Epub 2011 Mar 23.

PMID:
21429939
4.

Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa.

Köhler T, Perron GG, Buckling A, van Delden C.

PLoS Pathog. 2010 May 6;6(5):e1000883. doi: 10.1371/journal.ppat.1000883.

5.

[Effects of azithromycin on the virulence of Pseudomonas aeruginosa].

Reinert P.

Pathol Biol (Paris). 1995 Jun;43(6):551-3. French.

PMID:
8539081
6.

In vivo imaging of the lung inflammatory response to Pseudomonas aeruginosa and its modulation by azithromycin.

Stellari F, Bergamini G, Sandri A, Donofrio G, Sorio C, Ruscitti F, Villetti G, Assael BM, Melotti P, Lleo MM.

J Transl Med. 2015 Aug 4;13:251. doi: 10.1186/s12967-015-0615-9.

7.

Pseudomonas aeruginosa: an uninvited guest refuses to leave.

Hauser AR.

Am J Respir Crit Care Med. 2008 Sep 1;178(5):438-9. doi: 10.1164/rccm.200805-789ED. No abstract available.

PMID:
18713847
8.

Pseudomonas aeruginosa-catecholamine inotrope interactions: a contributory factor in the development of ventilator-associated pneumonia?

Freestone PP, Hirst RA, Sandrini SM, Sharaff F, Fry H, Hyman S, O'Callaghan C.

Chest. 2012 Nov;142(5):1200-1210. doi: 10.1378/chest.11-2614.

PMID:
22556319
9.

Resistance rates of Pseudomonas aeruginosa and Acinetobacter species causing ventilator-associated pneumonia do not always correlate with utilisation of antibiotics.

Jankovic S, Djordjevic Z, Matovic M.

J Hosp Infect. 2011 Jan;77(1):77-8. doi: 10.1016/j.jhin.2010.09.015. Epub 2010 Dec 3. No abstract available.

PMID:
21122946
10.

Improving the adequacy of empirical beta-lactam therapy for Pseudomonas aeruginosa ventilator-associated pneumonia.

Depuydt P, Blot S, Benoit D, Decruyenaere J.

Int J Antimicrob Agents. 2008 May;31(5):489-90. doi: 10.1016/j.ijantimicag.2008.01.001. Epub 2008 Mar 4. No abstract available.

PMID:
18313271
11.

Nebulized imipenem to control nosocomial pneumonia caused by Pseudomonas aeruginosa.

Radhakrishnan M, Jaganath A, Rao GS, Kumari HB.

J Crit Care. 2008 Mar;23(1):148-50. doi: 10.1016/j.jcrc.2007.10.037. No abstract available.

PMID:
18359432
12.

Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials.

Siempos II, Ntaidou TK, Falagas ME.

Crit Care Med. 2010 Mar;38(3):954-62. doi: 10.1097/CCM.0b013e3181c8fe4b.

PMID:
20016381
13.

Pseudomonas aeruginosa: so many virulence factors, so little time.

Hauser AR.

Crit Care Med. 2011 Sep;39(9):2193-4. doi: 10.1097/CCM.0b013e318221742d. No abstract available.

14.

Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.

Gelfand MS, Cleveland KO.

Clin Infect Dis. 2015 Sep 1;61(5):853-5. doi: 10.1093/cid/civ411. Epub 2015 May 28. No abstract available.

PMID:
26021991
15.

Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organisms from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug.

Zavascki AP, Li J, Nation RL, Superti SV, Barth AL, Lutz L, Ramos F, Boniatti MM, Goldani LZ.

J Clin Microbiol. 2009 Sep;47(9):3064-5. doi: 10.1128/JCM.01035-09. Epub 2009 Jul 8. No abstract available.

16.

Relative contribution of three main virulence factors in Pseudomonas aeruginosa pneumonia.

Le Berre R, Nguyen S, Nowak E, Kipnis E, Pierre M, Quenee L, Ader F, Lancel S, Courcol R, Guery BP, Faure K; Pyopneumagen Group.

Crit Care Med. 2011 Sep;39(9):2113-20. doi: 10.1097/CCM.0b013e31821e899f.

PMID:
21572326
17.

Ventilator-associated pneumonia caused by Pseudomonas aeruginosa: cap your needles!

Hauser AR.

Crit Care Med. 2012 Aug;40(8):2503-4. doi: 10.1097/CCM.0b013e318258e5bb. No abstract available.

18.

Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial.

François B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, Misset B, Andremont A, Ploy MC, Jacobs A, Yarranton G, Pearce T, Fagon JY, Chastre J.

Crit Care Med. 2012 Aug;40(8):2320-6. doi: 10.1097/CCM.0b013e31825334f6.

PMID:
22622405
19.

Quorum sensing-dependent virulence during Pseudomonas aeruginosa colonisation and pneumonia in mechanically ventilated patients.

Köhler T, Guanella R, Carlet J, van Delden C.

Thorax. 2010 Aug;65(8):703-10. doi: 10.1136/thx.2009.133082.

PMID:
20685744
20.

Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres.

Smith DJ, Ramsay KA, Yerkovich ST, Reid DW, Wainwright CE, Grimwood K, Bell SC, Kidd TJ.

Respirology. 2016 Feb;21(2):329-37. doi: 10.1111/resp.12714. Epub 2015 Dec 28.

Supplemental Content

Support Center